HC Wainwright Weighs in on Humacyte FY2028 Earnings

Humacyte, Inc. (NASDAQ:HUMA) – Investment analysts at HC Wainwright issued their FY2028 earnings per share (EPS) estimates for Humacyte in a report released on Tuesday, November 5th. HC Wainwright analyst V. Bernardino anticipates that the company will post earnings per share of $0.71 for the year. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.09) per share.

Several other research firms have also recently issued reports on HUMA. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a research note on Friday, September 20th. BTIG Research reiterated a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. Benchmark reissued a “buy” rating and set a $15.00 price objective on shares of Humacyte in a research note on Thursday, October 10th. Piper Sandler set a $6.00 target price on Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. Finally, TD Cowen reaffirmed a “buy” rating and issued a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $11.00.

Humacyte Trading Up 4.0 %

Shares of Humacyte stock opened at $5.43 on Wednesday. The company’s 50-day moving average price is $5.49 and its 200-day moving average price is $6.12. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.61. Humacyte has a 12-month low of $2.08 and a 12-month high of $9.97. The company has a market cap of $648.07 million, a price-to-earnings ratio of -4.31 and a beta of 1.47.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04).

Insider Buying and Selling

In other Humacyte news, Director Kathleen Sebelius sold 5,182 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total transaction of $27,982.80. Following the sale, the director now owns 40,276 shares in the company, valued at $217,490.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, Director Brady W. Dougan sold 252,676 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total value of $1,695,455.96. Following the completion of the sale, the director now owns 4,306,464 shares of the company’s stock, valued at approximately $28,896,373.44. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kathleen Sebelius sold 5,182 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total transaction of $27,982.80. Following the transaction, the director now directly owns 40,276 shares in the company, valued at approximately $217,490.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,084,153 shares of company stock worth $6,869,996. Corporate insiders own 11.20% of the company’s stock.

Institutional Trading of Humacyte

Several institutional investors have recently added to or reduced their stakes in the business. Private Advisor Group LLC increased its holdings in shares of Humacyte by 232.7% in the first quarter. Private Advisor Group LLC now owns 317,624 shares of the company’s stock worth $988,000 after buying an additional 222,144 shares during the period. Vanguard Group Inc. increased its stake in Humacyte by 28.7% in the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock worth $12,501,000 after purchasing an additional 896,415 shares during the period. Anson Funds Management LP bought a new stake in Humacyte in the first quarter valued at approximately $156,000. Virtu Financial LLC purchased a new stake in shares of Humacyte during the first quarter valued at approximately $197,000. Finally, ARS Investment Partners LLC bought a new position in shares of Humacyte in the second quarter worth approximately $559,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.